JP2019513777A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513777A5 JP2019513777A5 JP2018553871A JP2018553871A JP2019513777A5 JP 2019513777 A5 JP2019513777 A5 JP 2019513777A5 JP 2018553871 A JP2018553871 A JP 2018553871A JP 2018553871 A JP2018553871 A JP 2018553871A JP 2019513777 A5 JP2019513777 A5 JP 2019513777A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- epitope
- tumor
- construct
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323432P | 2016-04-15 | 2016-04-15 | |
| US62/323,432 | 2016-04-15 | ||
| PCT/CA2017/050463 WO2017177337A1 (en) | 2016-04-15 | 2017-04-13 | Multi-specific antigen-binding constructs targeting immunotherapeutics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019513777A JP2019513777A (ja) | 2019-05-30 |
| JP2019513777A5 true JP2019513777A5 (https=) | 2020-05-28 |
Family
ID=60042760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553871A Pending JP2019513777A (ja) | 2016-04-15 | 2017-04-13 | 免疫療法薬を標的とする多重特異性抗原結合構築物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190111079A1 (https=) |
| EP (1) | EP3443014A4 (https=) |
| JP (1) | JP2019513777A (https=) |
| KR (1) | KR20180135460A (https=) |
| CN (1) | CN109153727A (https=) |
| AU (1) | AU2017251116A1 (https=) |
| BR (1) | BR112018070676A2 (https=) |
| CA (1) | CA3021634A1 (https=) |
| MX (1) | MX2018012468A (https=) |
| RU (1) | RU2018139811A (https=) |
| WO (1) | WO2017177337A1 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CN110944661A (zh) | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| US20200306375A1 (en) * | 2017-02-22 | 2020-10-01 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
| AU2018225164A1 (en) * | 2017-02-22 | 2019-09-19 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| SG11202004116QA (en) | 2017-11-08 | 2020-06-29 | Biontech Us Inc | T cell manufacturing compositions and methods |
| CN111315405A (zh) * | 2017-11-09 | 2020-06-19 | 免疫医疗有限责任公司 | 双特异性融合多肽及其使用方法 |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| TWI822726B (zh) | 2018-02-26 | 2023-11-21 | 德商梅迪基因免疫治療公司 | Ｎｙｅｓｏ ｔ細胞受體 |
| KR20210018275A (ko) * | 2018-05-07 | 2021-02-17 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질 |
| CN110507824A (zh) * | 2018-05-21 | 2019-11-29 | 荣昌生物制药（烟台）有限公司 | 一种抗间皮素抗体及其抗体药物缀合物 |
| KR102870868B1 (ko) | 2018-06-01 | 2025-10-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| WO2020084608A1 (en) * | 2018-10-22 | 2020-04-30 | Explore Bio 1 Ltd | Precursor bispecific antibody constructs and methods of use thereof |
| SG11202104180WA (en) * | 2018-10-30 | 2021-05-28 | Peter Maccallum Cancer Inst | Bispecific polypeptides for engagement of car expressing immune cells with antigen presenting cells and uses thereof |
| AU2019372673A1 (en) * | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| US20220089719A1 (en) * | 2019-01-08 | 2022-03-24 | Labyrx Immunologic Therapeutics (Usa) Limited | Constructs targeting labyrinthin or a portion thereof and uses thereof |
| CN113646334B (zh) * | 2019-02-20 | 2025-09-16 | 国家儿童医院研究所 | 癌症靶向的、病毒编码的、可调节的t细胞（catvert）或nk细胞（catvern）接头 |
| CN118994397A (zh) * | 2019-05-21 | 2024-11-22 | 诺华股份有限公司 | 针对bcma的三特异性结合分子及其用途 |
| JP7489407B2 (ja) | 2019-05-21 | 2024-05-23 | ノバルティス アーゲー | Ｃｄ１９結合分子及びその使用 |
| RS66218B1 (sr) | 2019-07-01 | 2024-12-31 | Tonix Pharma Ltd | Anti-cd154 antitela i njihove upotrebe |
| WO2021057906A1 (zh) * | 2019-09-25 | 2021-04-01 | 科济生物医药（上海）有限公司 | 表达il-15的免疫效应细胞 |
| CN111235113A (zh) * | 2020-01-21 | 2020-06-05 | 南京北恒生物科技有限公司 | 包含嵌合抗原受体的免疫细胞及其用途 |
| JP7512394B2 (ja) | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| GB202008688D0 (en) * | 2020-06-09 | 2020-07-22 | Cancer Research Tech Ltd | Chimeric antigen receptor cell |
| US20240000937A1 (en) * | 2020-09-22 | 2024-01-04 | World Biotech Regenerative Medical Group Limited | Methods and compositions of car-expressing natural killer cells with bispecific antigen-binding molecules as cancer therapeutic agents |
| WO2022150452A1 (en) | 2021-01-06 | 2022-07-14 | Seth Lederman | Methods of inducing immune tolerance with modified anti-cd154 antibodies |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| IL309208A (en) | 2021-06-11 | 2024-02-01 | Sage Therapeutics Inc | Neuroactive steroid for the treatment of alzheimer's disease |
| CN117897404A (zh) * | 2021-08-02 | 2024-04-16 | 信达生物制药(苏州)有限公司 | 抗CD79b×CD3双特异性抗体及其用途 |
| US20250002574A1 (en) * | 2021-08-12 | 2025-01-02 | Sunshine Lake Pharma Co., Ltd. | Il-11 humanized antibody and application thereof |
| EP4405379A4 (en) * | 2021-09-24 | 2025-08-20 | Synergy Imt Inc | COMPOSITION OF RECOMBINANT ANTIGEN-BINDING MOLECULES AND METHOD OF MANUFACTURE AND USE THEREOF |
| TW202340474A (zh) * | 2022-01-11 | 2023-10-16 | 大陸商深圳市珈鈺生物科技有限公司 | 樹突細胞腫瘤疫苗和其用途 |
| CN115368446B (zh) * | 2022-07-19 | 2025-08-08 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| JP2026502768A (ja) | 2022-10-25 | 2026-01-27 | アブレクシス， エルエルシー | 抗ｃｄ３抗体 |
| WO2024107731A2 (en) | 2022-11-14 | 2024-05-23 | Ablexis, Llc | Anti-pd-l1 antibodies |
| CN121127253A (zh) * | 2023-02-28 | 2025-12-12 | 朱诺治疗学股份有限公司 | 治疗系统性自身免疫性疾病的细胞疗法 |
| TW202547884A (zh) * | 2024-03-15 | 2025-12-16 | 美商艾爾維克醫療公司 | Ｍｕｃ１６／ｎａｐｉ－２ｂ抗體及使用方法 |
| CN117965633A (zh) * | 2024-04-01 | 2024-05-03 | 北京双赢科创生物科技有限公司 | 一种IFNγ受体敲除的CAR-T细胞的制备方法与应用 |
| WO2025248134A1 (en) | 2024-05-31 | 2025-12-04 | Tonix Pharma Limited | Treatment methods comprising administration of modified cd154 antibodies |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2825553B1 (en) * | 2012-03-14 | 2018-07-25 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
| KR20150008171A (ko) * | 2012-05-10 | 2015-01-21 | 자임워크스 인코포레이티드 | 단일군 일가 항체 구조물 및 그의 용도 |
| BR112014029417B1 (pt) * | 2012-05-25 | 2023-03-07 | Cellectis | Método ex vivo para a preparação de células t para imunoterapia |
| AU2013289883B2 (en) * | 2012-07-13 | 2018-11-01 | Zymeworks Bc Inc. | Bispecific asymmetric heterodimers comprising anti-CD3 constructs |
| EP3508215A3 (en) * | 2012-12-03 | 2019-10-02 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
| CA2913052A1 (en) * | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| NZ759969A (en) * | 2013-12-20 | 2022-12-23 | Fred Hutchinson Cancer Center | Tagged chimeric effector molecules and receptors thereof |
| WO2015121454A1 (en) * | 2014-02-14 | 2015-08-20 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| CA2964958A1 (en) * | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Methods and compositions for modified t cells |
| US10617720B2 (en) * | 2016-10-20 | 2020-04-14 | Miltenyi Biotech, GmbH | Chimeric antigen receptor specific for tumor cells |
-
2017
- 2017-04-13 CA CA3021634A patent/CA3021634A1/en not_active Abandoned
- 2017-04-13 WO PCT/CA2017/050463 patent/WO2017177337A1/en not_active Ceased
- 2017-04-13 BR BR112018070676A patent/BR112018070676A2/pt not_active IP Right Cessation
- 2017-04-13 MX MX2018012468A patent/MX2018012468A/es unknown
- 2017-04-13 CN CN201780027726.6A patent/CN109153727A/zh active Pending
- 2017-04-13 JP JP2018553871A patent/JP2019513777A/ja active Pending
- 2017-04-13 AU AU2017251116A patent/AU2017251116A1/en not_active Abandoned
- 2017-04-13 RU RU2018139811A patent/RU2018139811A/ru not_active Application Discontinuation
- 2017-04-13 KR KR1020187031618A patent/KR20180135460A/ko not_active Ceased
- 2017-04-13 EP EP17781690.7A patent/EP3443014A4/en not_active Withdrawn
- 2017-04-13 US US16/088,760 patent/US20190111079A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513777A5 (https=) | ||
| Park et al. | Targets and antibody formats for immunotherapy of neuroblastoma | |
| RU2018139811A (ru) | Мультиспецифические антигенсвязывающие конструкции, нацеливающие иммунотерапевтические средства | |
| van de Donk et al. | T-cell-engaging bispecific antibodies in cancer | |
| JP2020525032A5 (https=) | ||
| JP2017531427A5 (https=) | ||
| Weiner et al. | Monoclonal antibodies for cancer immunotherapy | |
| JP2019536430A5 (https=) | ||
| Niquille et al. | Biparatopic antibodies: therapeutic applications and prospects | |
| JP2017532952A5 (https=) | ||
| JP2018527919A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
| MY205758A (en) | Anti-nkg2a antibodies and uses thereof | |
| JP2020515247A5 (https=) | ||
| JP2014527814A5 (https=) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2015517470A5 (https=) | ||
| JP2019511222A5 (https=) | ||
| JP2016507555A5 (https=) | ||
| JP2017506217A5 (https=) | ||
| JP2013227339A5 (https=) | ||
| WO2016191643A4 (en) | Tigit-binding agents and uses thereof | |
| JP2018508483A5 (https=) | ||
| JP2013527761A5 (https=) |